Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE

Maddalena Sansovini,Stefano Severi,Annarita Ianniello,Silvia Nicolini,Lorenzo Fantini,E. Mezzenga,Fabio Ferroni,Emanuela Scarpi,Manuela Monti,Alberto Bongiovanni,Sara Cingarlini,Chiara Grana,Lisa Bodei,Giovanni Paganelli

Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE

2017

Maddalena Sansovini
Stefano Severi
Annarita Ianniello
Silvia Nicolini
Lorenzo Fantini
E. Mezzenga
Fabio Ferroni
Emanuela Scarpi
Manuela Monti
Alberto Bongiovanni
Sara Cingarlini
Chiara Grana
Lisa Bodei
Giovanni Paganelli

Purpose Lu-DOTATATE (Lu-PRRT) is a valid therapeutic option in differentiated pancreatic neuroendocrine tumors (P-NETs). FDG PET seems to be an important prognostic factor in P-NETs. We evaluated the efficacy of Lu-PRRT and the role of FDG PET in 60 patients with advanced P-NETs.

Keywords:

Radiology
177Lu-DOTATATE
Medicine
Pathology
Neuroendocrine tumors
Positron Emission Tomography-Computed Tomography
Predictive value of tests
Octreotide
Nuclear medicine
long term follow up
prognostic factor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations